Dr. Judah Folkman honored with American Heart Association/Novartis award

September 17, 2003

Three decades of study in tumor angiogenesis result in new insight into hypertension

WASHINGTON, D.C., Sept. 17 - Judah Folkman, M.D., is the winner of this year's Novartis Award for Hypertension Research. He is a pioneer in the field of angiogenesis, which is how the body generates new blood vessels. His work has led to a better understanding of how angiogenesis is related to hypertension and how stopping the process when it goes awry is an important goal for new antihypertension treatments.

The American Heart Association's Council for High Blood Pressure Research gives the award at its annual meeting to recognize major research advances. Since 1975, the Novartis Award annually recognizes the most important research contributing to improved treatment and greater understanding of high blood pressure.

A professor of pediatric surgery and professor of cell biology at Children's Hospital and Harvard Medical School, Boston, Folkman has dedicated more than three decades to angiogenesis research. The field was started to understand how cancer stimulates its own blood vessel growth, but a chain of discoveries led to a better understanding of how the mechanism of angiogenesis affects blood vessels leading to the heart.

In the early 1970s, Folkman and colleagues were among the first to grow endothelial cells (cells that line the blood vessels) in a dish. Though seemingly insignificant, the discovery was a breakthrough in medicine leading to a better understanding of how endothelial cell growth fosters cancer and heart disease.

Being able to study endothelial cells in a dish led to Folkman and colleagues' discovery of an entire set of molecules that turn off endothelial growth. He was among the researchers to discover a protein named endostatin that inhibits not only blood vessel growth that nourishes cancer but also the growth of atherosclerotic plaque as demonstrated by Karen Moulton, M.D., in Folkman's lab. Maria Rupnick, Ph.D., also in Folkman's lab, showed that angiogenesis inhibitors like endostatin turn off growing endothelial cells in the fat of obese mice, causing the fat to disappear.

"In all these cases, endothelial cell and smooth muscle growth contribute to high blood pressure. Endothelial cells are able to produce molecules that control how much smooth muscle you have in the artery walls. Overgrowth of smooth muscle cells contributes to high blood pressure," Folkman said. His contributions are leading to new treatments for high blood pressure and cancer. "One would think, at first, that there is no connection between cancer and high blood pressure. The connection is angiogenesis, or how small blood vessels grow. Those molecules that make them grow or keep them from growing are used in the wall of the blood vessel for other purposes -- either to prevent high blood pressure or induce it," he said. "The research that we've done in angiogenesis in cancer has provided researchers in hypertension with new molecules and a new understanding of their field. Since 1980, we have discovered 11 angiogenesis inhibitors, and seven of those are in clinical trials."

Now, Folkman and his colleagues are turning their attention to how to prevent angiogenesis from occurring. This could lead to a better understanding of how to prevent high blood pressure, which affects as many as 50 million Americans, age six and older.

Folkman graduated cum laude from Ohio State University, Columbus, Ohio, and magna cum laude from Harvard Medical School. He completed his surgical residency at Massachusetts General Hospital, where he served as chief resident in the mid-1960s.

Folkman holds honorary degrees from 12 universities and has received more than 100 awards. He was elected to the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences.
The Novartis Award for Hypertension Research is supported by Novartis Pharmaceuticals Corp.

American Heart Association

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.